ClinicalTrials.gg
Drug

Tenofovir alafenamide clinical trials

Also written Vemlidy, TAF and GS-7340.

studies test it
140
open now
25
in phase 3
41
first study started
2002
Related medicines add 2 studies

Counted the way a researcher would: Tenofovir alafenamide with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses tenofovir alafenamide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tenofovir alafenamide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
5 Nov 2015 · GENVOYA · NDA 207561 (FDA, Drugs@FDA; in a combination)
European Union
19 Nov 2015 · Genvoya · EMEA/H/C/004042 (EMA; in a combination)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tenofovir Alafenamide
28
Tenofovir Alafenamide 25 MG
6
Tenofovir Alafenamide (TAF)
6
Tenofovir alafenamide fumarate
4
GS-9883/F/TAF
2

Brand

Vemlidy
26

Development codes

GS-7340
9
TAF 25mg
1

Other names

TAF
23

In one entry with another drug

Given together, or one or the other

B/F/TAF
19
E/C/F/TAF
18
F/TAF
9
Bictegravir/emtricitabine/tenofovir alafenamide
6
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC
4
TMC114/JNJ-48763364/JNJ-35807551/JNJ-63625328
2
BIC/FTC/TAF
2

Studies by the year they started

140 studies that test it; most in 2021 (17)

Studies that test tenofovir alafenamide, by start year
YearStudies
20021
20101
20111
20123
20138
20145
201514
201611
20179
201812
201915
202014
202117
20225
20232
20247
20257
20268

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
21
Phase 2
23
Phase 3
41
Phase 4
50
No phase
11

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 62 · Other 78

Gilead Sciences (49) · Third Affiliated Hospital, Sun Yat-Sen University (6) · Janssen Sciences Ireland UC (3) · Young-Suk Lim (2) · Taichung Veterans General Hospital (2) · National Taiwan University Hospital (2) · Fundacion SEIMC-GESIDA (2) · The Third Affiliated Hospital of Guangzhou Medical University (2)

Often tested with

Tested in the same studies.

Emtricitabine (68) · Bictegravir (33) · Cobicistat (28) · Elvitegravir (20) · Darunavir (13) · Dolutegravir (7) · Lenacapavir (5) · Emtricitabine tenofovir alafenamide (5)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 8 phase 3 studies under way

Tenofovir alafenamide is the comparator. A study of two new drugs counts under both.

  • 3Islatravir · Merck Sharp & Dohme LLC · next primary completion Feb 2029
  • 2Lamivudine · ViiV Healthcare, José Antonio Mata Marín
  • 1Bictegravir · Gilead Sciences
  • 1Lenacapavir · Gilead Sciences
  • 1Dolutegravir · ViiV Healthcare
  • 1Lepetegravir · Gilead Sciences · next primary completion Jan 2028
  • 1Ulonivirine · Merck Sharp & Dohme LLC · next primary completion Feb 2029
  • 1Azvudine · Zhigang Ren · next primary completion Dec 2026
Reaching primary completion within a year · 8, 1 in phase 3

Studies that test tenofovir alafenamide, phase 3 first.

Studies

Open first, then newest update. How each study uses tenofovir alafenamide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 140

See all 140 studies that test tenofovir alafenamide →

Given beside what is tested · 39 — tenofovir alafenamide is usual care or a partner of the new treatment

Showing 20 of 39.

As the comparator · 22 — what is tested is compared with tenofovir alafenamide

Showing 20 of 22.

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting1

Codes

What other systems call tenofovir alafenamide · ClinicalTrials.gg INT004405

  • MeSH (NLM) C442442tenofovir alafenamideConfirmed NLM, Wikidata
  • UNII (FDA) EL9943AG5JTENOFOVIR ALAFENAMIDEConfirmed FDA, NLM, Wikidata
  • RxNorm 1721603Confirmed FDA, Wikidata
  • Wikidata Q22075912tenofovir alafenamideConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C148276Tenofovir AlafenamideOne source FDA
  • DrugBank DB09299One source Wikidata

Also registered as tenofovir alafenamide fumarate (UNII FWF6Q91TZO · RxNorm 1721604).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.